An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes

Alessandra Puddu, François MacH, Alessio Nencioni, Giorgio Luciano Viviani, Fabrizio Montecucco

Research output: Contribution to journalArticle

Abstract

Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.

Original languageEnglish
Article number591056
JournalMediators of Inflammation
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Advanced Glycosylation End Products
Glucagon-Like Peptide 1
Hyperglycemia
Type 2 Diabetes Mellitus
Eating
Proglucagon
Glucose
Diabetic Angiopathies
Endocrine Cells
Gastric Emptying
Glucagon
Hypoglycemic Agents
Insulin Resistance
Blood Glucose
Homeostasis
Epithelial Cells
Hormones
Insulin
Food
Genes

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. / Puddu, Alessandra; MacH, François; Nencioni, Alessio; Viviani, Giorgio Luciano; Montecucco, Fabrizio.

In: Mediators of Inflammation, Vol. 2013, 591056, 2013.

Research output: Contribution to journalArticle

Puddu, Alessandra ; MacH, François ; Nencioni, Alessio ; Viviani, Giorgio Luciano ; Montecucco, Fabrizio. / An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. In: Mediators of Inflammation. 2013 ; Vol. 2013.
@article{dd05f2ed144146f8970349f9f4118778,
title = "An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes",
abstract = "Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.",
author = "Alessandra Puddu and Fran{\cc}ois MacH and Alessio Nencioni and Viviani, {Giorgio Luciano} and Fabrizio Montecucco",
year = "2013",
doi = "10.1155/2013/591056",
language = "English",
volume = "2013",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes

AU - Puddu, Alessandra

AU - MacH, François

AU - Nencioni, Alessio

AU - Viviani, Giorgio Luciano

AU - Montecucco, Fabrizio

PY - 2013

Y1 - 2013

N2 - Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.

AB - Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84873403513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873403513&partnerID=8YFLogxK

U2 - 10.1155/2013/591056

DO - 10.1155/2013/591056

M3 - Article

C2 - 23365488

AN - SCOPUS:84873403513

VL - 2013

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 591056

ER -